| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANR.1780320909 |
| P698 | PubMed publication ID | 2775320 |
| P50 | author | Martin G Larson | Q37390385 |
| P2093 | author name string | M H Liang | |
| P H Schur | |||
| S A Socher | |||
| P433 | issue | 9 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| immunology | Q101929 | ||
| rheumatology | Q327657 | ||
| P304 | page(s) | 1107-1118 | |
| P577 | publication date | 1989-09-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus | |
| P478 | volume | 32 |
| Q67483551 | 'Run out and get me a four-year-old child' |
| Q37456300 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis |
| Q67774884 | A Randomized Trial of Plasmapheresis and Subsequent Pulse Cyclophosphamide in Severe Lupus: Design of the Lpsg Trial |
| Q54714606 | A comparison of patients' and physicians' assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. |
| Q36854313 | A compass that points to lupus: genetic studies on type I interferon pathway. |
| Q33777430 | A conceptual framework for clinical trials in SLE and other multisystem diseases |
| Q41926759 | A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus |
| Q43772908 | A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus |
| Q53931682 | A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. |
| Q33762839 | A genomic approach to human autoimmune diseases |
| Q38504890 | A greater variability in the 3' flanking region of the IL-6 gene in patients with systemic lupus erythematosus (SLE). |
| Q37308037 | A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus |
| Q40378212 | A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus |
| Q36660670 | A review of health related quality of life in systemic lupus erythematosus |
| Q33330951 | A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response |
| Q33915419 | Accelerated atheroma in lupus--background |
| Q36786721 | Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study |
| Q33635924 | Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII) |
| Q53816338 | Alexithymia and pain in three chronic pain samples: comparing Caucasians and African Americans. |
| Q35609293 | Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients |
| Q48435382 | An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life |
| Q47967726 | Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period |
| Q34044918 | Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort |
| Q83459571 | Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China |
| Q41210992 | Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations |
| Q81128351 | Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates |
| Q71682225 | Anti-neutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus |
| Q51065242 | Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study. |
| Q41260413 | Assessment of lupus: where are we now? |
| Q37160132 | Association between depression and coronary artery calcification in women with systemic lupus erythematosus |
| Q36784328 | Association between depression and vascular disease in systemic lupus erythematosus |
| Q35207176 | Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis |
| Q80149503 | Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus |
| Q47921621 | Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore |
| Q63369674 | Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides |
| Q58190143 | Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus |
| Q52684685 | Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. |
| Q35602526 | B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels |
| Q72013497 | Behçet's disease |
| Q52865109 | Behçet's disease: evaluation of a new instrument to measure clinical activity. |
| Q37994309 | Biomarkers for systemic lupus erythematosus |
| Q57350420 | Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone |
| Q70489689 | Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE) |
| Q30984296 | Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report |
| Q79368321 | Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies |
| Q34760339 | Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. |
| Q33723371 | Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside |
| Q33379920 | Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. |
| Q41945144 | Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients |
| Q41943280 | Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus |
| Q64980126 | Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. |
| Q35609787 | Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus |
| Q45738754 | Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus |
| Q72216074 | Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus |
| Q35039935 | Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus |
| Q43275143 | Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center |
| Q35973810 | Classification criteria for systemic lupus erythematosus: a review |
| Q67824072 | Clinical Features of Patients with Mild Systemic Lupus Erythematosus |
| Q34056359 | Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population |
| Q86015625 | Clinical applications of the indirect immunofluorescence assay for detection of anticell membrane-associated DNA antibodies in juvenile systemic lupus erythematosus |
| Q34844623 | Clinical outcome measures for cutaneous lupus erythematosus |
| Q35609121 | Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus |
| Q55691902 | Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. |
| Q45239422 | Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis |
| Q48133138 | Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus |
| Q39946264 | Colour Doppler ultrasound of the ocular circulation in patients with systemic lupus erythematosus identifies altered microcirculatory haemodynamics |
| Q34309764 | Combination treatment in autoimmune diseases: systemic lupus erythematosus. |
| Q83322949 | Comparison of a self-report and performance-based test of disability in people with systemic lupus erythematosus |
| Q48618855 | Comparison of neuropsychological impairment and vocational outcomes in systemic lupus erythematosus and multiple sclerosis patients |
| Q58161234 | Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians |
| Q47398030 | Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus |
| Q44081617 | Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients |
| Q37811971 | Criteria to define response to therapy in paediatric rheumatic diseases |
| Q38660157 | Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE) |
| Q53902963 | Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. |
| Q58192318 | Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus |
| Q47823630 | Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. |
| Q41644094 | Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta |
| Q43772904 | Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus |
| Q42459448 | Defective early T and T-dependent B cell activation in systemic lupus erythematosus |
| Q67925068 | Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study |
| Q35553688 | Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. |
| Q46448019 | Depression predicts self-reported disease activity in systemic lupus erythematosus |
| Q64254864 | Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment |
| Q33563706 | Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. |
| Q33777435 | Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials |
| Q33386907 | Discordant assessment of lupus activity between patients and their physicians: the Singapore experience |
| Q37356406 | Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. |
| Q38148751 | Disease activity measures in paediatric rheumatic diseases |
| Q44289531 | Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study |
| Q33377578 | Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus |
| Q40471904 | Disease assessment indices: activity, damage and severity. |
| Q64122608 | Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study |
| Q42362971 | Down-regulation of MBD4 contributes to hypomethylation and overexpression of CD70 in CD4+ T cells in systemic lupus erythematosus |
| Q47876362 | Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study |
| Q33635928 | Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). |
| Q56690071 | Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: A randomized controlled trial |
| Q38466691 | Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study |
| Q34118894 | Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose |
| Q30828464 | Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus |
| Q33957431 | Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology |
| Q58620300 | Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus |
| Q34051962 | Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus |
| Q36990282 | Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity |
| Q57612823 | European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients |
| Q53151257 | Evaluating systemic lupus erythematosus patients for lung involvement. |
| Q43433841 | Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus. |
| Q38101012 | Experiences and perspectives of adults living with systemic lupus erythematosus: thematic synthesis of qualitative studies. |
| Q54334960 | Extracorporeal photochemotherapy for the treatment of lupus erythematosus: preliminary observations. |
| Q33379277 | Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. |
| Q36302250 | Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort |
| Q34169570 | Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). |
| Q33380972 | Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort |
| Q72177020 | Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy |
| Q41074476 | Fish oil in lupus nephritis: clinical findings and methodological implications |
| Q28081809 | From BILAG to BILAG-based combined lupus assessment-30 years on |
| Q33579349 | Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus |
| Q36972054 | Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations |
| Q47927593 | Higher genetic susceptibility to inflammation in mild disease activity of systemic lupus erythematosus |
| Q36503702 | Host-microflora interaction in systemic lupus erythematosus (SLE): circulating antibodies to the indigenous bacteria of the intestinal tract |
| Q36504040 | Host-microflora interaction in systemic lupus erythematosus (SLE): colonization resistance of the indigenous bacteria of the intestinal tract |
| Q37211247 | How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets |
| Q41336601 | Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling |
| Q37354525 | Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production |
| Q34523855 | ICF core sets: how to specify impairment and function in systemic lupus erythematosus |
| Q72011183 | IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report |
| Q51973028 | Illness intrusiveness explains race-related quality-of-life differences among women with systemic lupus erythematosus. |
| Q74425869 | Immunophenotyping of lymphocyte T and B in the peripheral blood of systemic lupus erythematosus |
| Q53580496 | Impact of disease activity and cumulative damage on the health of lupus patients. |
| Q37434199 | Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico |
| Q30500527 | Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases |
| Q37271965 | Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients |
| Q42199801 | Incidence and risk of infection in egyptian patients with systemic lupus erythematosus |
| Q50492497 | Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. |
| Q42025177 | Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia |
| Q47398023 | Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption |
| Q37873914 | Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma |
| Q37819549 | International consensus for a definition of disease flare in lupus. |
| Q36093309 | Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans |
| Q33653146 | Is familial lupus different from sporadic lupus? Data from LUMINA (LXXIII), a multiethnic US cohort |
| Q43156843 | Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? |
| Q47742720 | Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. |
| Q57350902 | Longitudinal study of interleukin-10, tumor necrosis factor- α, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease |
| Q52320880 | Lupus community panel proposals for optimising clinical trials: 2018. |
| Q34226213 | Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage |
| Q36373318 | Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort |
| Q73604873 | Lupus nephritis |
| Q40506568 | Lupus pregnancies and neonatal lupus |
| Q40666454 | Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations |
| Q46428350 | Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus |
| Q37464804 | Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus |
| Q53509972 | Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. |
| Q37361089 | Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity |
| Q33853601 | Major peptide autoepitopes for nucleosome-specific T cells of human lupus |
| Q84140353 | Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity |
| Q77798496 | Measures of disease activity and damage in SLE |
| Q38010353 | Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythemato |
| Q26799223 | Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research |
| Q37914899 | Measuring outcomes in systemic lupus erythematosus clinical trials |
| Q41111692 | Measuring the quality of life of women with rheumatoid arthritis or systemic lupus erythematosus: a Swedish version of the Quality of Life Scale (QOLS) |
| Q36554724 | Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor |
| Q36016443 | Megakaryocyte progenitors are the main APCs inducing Th17 response to lupus autoantigens and foreign antigens |
| Q36513087 | Mercury in Hair Is Inversely Related to Disease Associated Damage in Systemic Lupus Erythematosus |
| Q40471892 | Methodological and statistical approaches to criteria development in rheumatic diseases. |
| Q34046983 | Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. |
| Q34143213 | Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus |
| Q51074626 | Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine. |
| Q53920423 | Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. |
| Q38223951 | Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity |
| Q26827651 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report |
| Q35169049 | Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being |
| Q40929944 | Nervous system lupus: pathogenesis and rationale for therapy |
| Q54620302 | Noninflammatory necrotizing vasculopathy in lupus nephritis: a single-center experience. |
| Q30409882 | Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus |
| Q51154761 | Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time |
| Q36600357 | Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement. |
| Q37204946 | Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study |
| Q37220152 | Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases |
| Q46908262 | Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms |
| Q33511924 | Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX) |
| Q52759733 | Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China. |
| Q33432006 | Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study |
| Q53063683 | Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. |
| Q34343779 | Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program |
| Q33555419 | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort |
| Q33424360 | Predictors of arthritis in pediatric patients with lupus |
| Q33448450 | Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort |
| Q30997109 | Predictors of intestinal pseudo-obstruction in systemic lupus erythematosus complicated by digestive manifestations: data from a Southern China lupus cohort |
| Q30956012 | Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort |
| Q31050711 | Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). |
| Q37659608 | Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. |
| Q37463003 | Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience |
| Q37391150 | Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus |
| Q61757085 | Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection |
| Q40536896 | Prolactin: a stimulator of disease activity in systemic lupus erythematosus |
| Q46308713 | Prospective Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus |
| Q34157817 | Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus |
| Q41375848 | Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE. |
| Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
| Q33776045 | Pulmonary function in children with systemic lupus erythematosus |
| Q34014604 | Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations |
| Q37749647 | Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues |
| Q67785704 | Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda |
| Q33564660 | Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations |
| Q41216030 | Reactivation of inactive systemic lupus erythematosus |
| Q41582396 | Recognition and management of systemic lupus erythematosus |
| Q35549820 | Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity |
| Q36771446 | Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity |
| Q33455049 | Relation between serological data at the time of biopsy and renal histology in lupus nephritis |
| Q37188698 | Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus |
| Q43581917 | Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus |
| Q30967796 | Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: data from the LUMINA cohort |
| Q71984986 | Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus |
| Q27014980 | Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review |
| Q57331110 | Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus |
| Q36257238 | Renal Interstitial Arteriosclerotic Lesions in Lupus Nephritis Patients: A Cohort Study from China |
| Q33411232 | Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort |
| Q33579224 | Restrictions of T cell receptor beta chain repertoire in the peripheral blood of patients with systemic lupus erythematosus |
| Q33341018 | Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage |
| Q33567589 | Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis |
| Q49216020 | Risk of infection in hospitalised children with systemic lupus erythematosus: a 10-year follow-up |
| Q36460981 | Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. |
| Q31129756 | Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). |
| Q44168826 | Serological detection of disease activity in SLE |
| Q36100610 | Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis? |
| Q45976427 | Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. |
| Q46146015 | Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus |
| Q73293880 | Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity |
| Q44029432 | Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis |
| Q37914499 | Social support and health in patients with systemic lupus erythematosus: a literature review. |
| Q71716928 | Soluble Fas molecule in the serum of patients with systemic lupus erythematosus |
| Q79934477 | Subclinical impairment of arterial mechanics in systemic lupus erythematosus identified by arterial waveform analysis |
| Q37327039 | Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus |
| Q71581580 | Systemic lupus erythematosus |
| Q50653655 | Systemic lupus erythematosus activity and beta two microglobulin levels. |
| Q46329612 | Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA) XXVII: factors predictive of a decline to low levels of disease activity |
| Q44148062 | Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage |
| Q33635868 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage |
| Q35637240 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study |
| Q35638310 | Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability |
| Q35637820 | Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time |
| Q46843827 | Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs Nurture |
| Q46684489 | Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory |
| Q44003915 | Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores |
| Q35873395 | Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis |
| Q46430510 | Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture |
| Q46388184 | Systemic lupus erythematosus in three ethnic groups: XV prevalence and correlates of fibromyalgia |
| Q33584094 | Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation |
| Q36673286 | Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. |
| Q55379196 | TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. |
| Q42467538 | Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). |
| Q37190011 | The BILAG-2004 index is sensitive to change for assessment of SLE disease activity |
| Q37591255 | The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus |
| Q36915684 | The Paediatric Rheumatology International Trials Organization (PRINTO). |
| Q41944686 | The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters |
| Q44723933 | The frequency of and associations with hospitalization secondary to lupus flares from the 1000 Faces of Lupus Canadian cohort. |
| Q36252876 | The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus |
| Q37327037 | The implication of tissue Doppler echocardiography and cardiopulmonary exercise in early detection of cardiac dysfunction in systemic lupus erythematosus patients |
| Q60302954 | The potential diagnostic utility of coexpression of Ki-67 and P53 in the renal biopsy in pediatric lupus nephritis |
| Q89699275 | The predictive value of crescents in the disease progression of lupus nephritis based on the 2018 International Society of Nephrology/Renal Pathology Society Revision System: a large cohort study from China |
| Q45038735 | The prevalence and associations of sleep disturbances in patients with systemic lupus erythematosus |
| Q53497194 | The rating scale preference measure as an evaluative measure in systemic lupus erythematosus. |
| Q41644086 | The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity |
| Q34681085 | The relationship between processing speed and working memory demand in systemic lupus erythematosus: Evidence from a visual n-back task |
| Q35191580 | The role of microRNA-1246 in the regulation of B cell activation and the pathogenesis of systemic lupus erythematosus |
| Q37308042 | The search for lupus biomarkers |
| Q33858548 | The soluble CD40 ligand sCD154 in systemic lupus erythematosus |
| Q33405303 | The spectrum of renal thrombotic microangiopathy in lupus nephritis |
| Q50758139 | The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. |
| Q33796222 | The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients |
| Q51300605 | Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. |
| Q64912490 | Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. |
| Q40573631 | Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus |
| Q37137299 | Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort |
| Q28766942 | Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort |
| Q37455235 | Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort |
| Q33527462 | Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study |
| Q34626276 | Toward the development of criteria for global flares in juvenile systemic lupus erythematosus |
| Q40978743 | Transition of Care and Health-Related Outcomes in Pediatric-Onset Systemic Lupus Erythematosus |
| Q33832953 | Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature |
| Q47258712 | Tubular basement membrane immune complex deposition is associated with activity and progression of lupus nephritis: a large multicenter Chinese study |
| Q53178492 | Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. |
| Q36628172 | Tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and their soluble receptors (sTNF-alpha-Rp55 and slL-6R) serum levels in systemic lupus erythematodes. |
| Q35550020 | UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial |
| Q33621131 | Understanding the epidemiology and progression of systemic lupus erythematosus |
| Q77424479 | Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus |
| Q64389051 | Urinary loss of immunoglobulin G anti-F(ab)2 and anti-DNA antibody in systemic lupus erythematosus nephritis |
| Q45904209 | Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis. |
| Q38077151 | Use of biomarkers in the management of children with lupus |
| Q61757090 | Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection |
| Q50765174 | Validation of a systemic lupus activity questionnaire (SLAQ) for population studies |
| Q47960264 | Validation of the Japanese version of the Systemic Lupus Activity Questionnaire that includes physician-based assessments in a large observational cohort. |
| Q37137321 | Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort |
| Q52916966 | Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. |
| Q41701246 | Validity of a vasculitis activity index for systemic necrotizing vasculitis |
| Q35609359 | Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus |
| Q37985709 | What do we know about self-reported fatigue in systemic lupus erythematosus? |
| Q44362369 | Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors |
| Q52002948 | Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. |
| Q73200573 | [Assay of plasma thrombomodulin in systemic diseases] |
| Q73969610 | [Oral manifestations in patients with systemic lupus erythematosus] |
| Q82663605 | [Systemic lupus erythematosus--activity and outcome] |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.